Stockhub

SpringWorks Therapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

14 August 2022

31 July 2022

  • curprev 08:5208:52, 31 July 2022 >Chris 1,767 bytes +1,767 Created page with "SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromat..."
Retrieved from "https://stockhub.co/research/SpringWorks_Therapeutics,_Inc."